Stanford Neuro-Immuno-Oncology Program Team


Crystal Mackall, MD
Founding Director
Center for Cancer Cell Therapy


Michelle Monje, MD, PhD
Founding Director

Associate Director
Center for Cancer Cell Therapy

Brian J. Scott, MD




Cynthia Campen, MD
Jasia Mahdi, MD
Elizabeth Mayne, MD, PhD
Michelle Monje, MD, PhD
Sonia Partap, MD, MS
Brian Scott, MD
Kun-Wei Song, MD
Kate Therkelsen, MD
Reena Thomas, MD, PhD

Hematology and Oncology

Catherine Aftandilian, MD
Jacquelyn Crane, MD
Kara Davis, DO
Tanja Gruber, MD
Jennifer Kamens, MD
Crystal Mackall, MD
Robbie Majzner, MD
Sneha Ramakrishna, MD
Raya Saab, MD
Liora Schultz, MD


Melanie Gephart, MD
Gordon Li, MD
Michael Lim, MD
Laura Prolo, MD, PhD

Critical Care

Timothy Cornell, MD
Lindsey Rasmussen, MD
Zachary Threlkeld, MD

Psychiatry and Behavioral Sciences

Sheila Lahijani, MD, FACLP

Advanced Practice Providers

May Casazza, NP
Divya Madhav, PA
Jen Moon, NP

Clinical Nurse Specialists

Theodora Kalatzi, RN
Clarissa Manez, RN

Nurse Coordinators

Courtney Erickson, RN
Ashley Jacobs, RN
Emily DeYager, RN

Social Worker

Maha Ghabris, LCSW

Clinical Trial Operations Team

Christina Baggott, RN, PhD
Sophie Bertrand
Sneha Jariwala
Leeza Kopaeva
Michael Kunicki
Jared Kwong
Amy Li
Alexandria Lim
Lewis Naya
Liza Reichert
Kelly Tanner
Hari Priya Yerraballa

Administrative Team

Barbara Beebe, MBA
Casey Carr, MHA

Affiliated Centers and Labs

Leadership Biographies

Founding Director

Associate Director
Center for Cancer Cell Therapy

Michelle Monje, MD, PhD

Michelle Monje is a Professor of Neurology and Neurological Sciences at Stanford University and a Howard Hughes Medical Institute Investigator. Her research program focuses at the intersection of neuroscience and brain cancer biology with an emphasis on neuron-glial interactions in health and oncological disease. Her lab demonstrated that neuronal activity regulates healthy glial precursor cell proliferation, new oligodendrocyte generation, and adaptive myelination; this plasticity of myelin contributes to healthy cognitive function, while disruption of myelin plasticity contributes to cognitive impairment in disease states like cancer therapy-related cognitive impairment. She discovered that neuronal activity similarly promotes the progression of malignant gliomas, driving glioma growth through both paracrine factors and through electrophysiologically functional neuron-to-glioma synapses. Dr. Monje has led several of her discoveries from basic molecular work to clinical trials. Her brain cancer neuroscience work has been recognized with numerous honors, including an NIH Director’s Pioneer Award, a MacArthur Fellowship and election to the National Academy of Medicine.


Brian J. Scott, MD

Brian J Scott, MD is a board-certified neurologist and Clinical Associate Professor of Neurology & Neurological Sciences with subspecialty board certification in neuro-oncology and neurocritical care. He is a graduate of the Tufts Neurology Residency program in Boston. After residency, he pursued a clinical neuro-oncology fellowship at the Partners combined Massachusetts General Hospital/Dana-Farber Cancer Institute program, where he developed expertise in the diagnosis and management of individuals with primary brain tumors, brain metastasis, central nervous system lymphoma, neurologic paraneoplastic syndromes, and complications of cancer therapy. He went on to complete the UCSF Neurohospitalist fellowship after which he remained on faculty at UCSF. He subsequently spent 4 years as the director of inpatient neurology and the medical director of neuro-oncology at the Lahey Hospital and Medical Center in Burlington, MA. He helped launch the neurocritical care unit at Lahey in 2015, and served as site PI on clinical trials for stroke and glioblastoma.  Dr. Scott joined the Stanford Neurohospitalist Program in 2017.

Dr. Scott is passionate about improving the system of acute care for individuals with neurologic illness. He has published on how to optimize care pathways for patients with complex neurologic disease, including CNS lymphoma and CAR T cell neurotoxicity. He is invested in thoughtful transitions of care and designed a series of projects to improve patients' knowledge about their medications. He loves teaching medical students and residents and has been selected for institutional and departmental teaching awards. He is the Associate Director of the Neurology Clerkship. He also serves as the faculty director of the resident-led Morbidity, Mortality, & Improvement conference.

Founding Director
Center for Cancer Cell Therapy

Crystal Mackall, MD

Crystal L Mackall, MD is the Ernest and Amelia Gallo Family Professor of Pediatrics and Internal Medicine at Stanford University. She serves as Founding Director of the Stanford Center for Cancer Cell Therapy, Associate Director of Stanford Cancer Institute, Leader of the Cancer Immunology and Immunotherapy Program and Director of the Parker Institute for Cancer Immunotherapy at Stanford. During a 27 year tenure culminating as Chief of the Pediatric Oncology Branch, NCI, and now through the Mackall Lab at Stanford, she has led an internationally recognized translational research program focused on immuno-oncology. She has conducted numerous early phase and first-in-human and first-in-child clinical trials spanning dendritic cell vaccines, cytokines, and adoptive immunotherapy using NK cells and genetically modified T cells. Her work is credited with identifying an essential role for the thymus in human T cell regeneration and discovering IL-7 as the master regulator of T cell homeostasis. Her group was among the first to demonstrate impressive activity of CD19-CAR in pediatric leukemia, developed a novel CD22-CAR with impressive activity in leukemia refractory to CD19 targeting and identified T cell exhaustion as a major feature limiting the activity of CAR T cells. Recently her group has developed a novel approach to prevent human T cell exhaustion. Dr. Mackall’s clinical trials are notable for incorporation of deep biologic endpoints that further our understanding of the basis for success and failure of novel immunotherapeutics.